Related Experiment Videos
Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy
M S Reddy1, T J Carmody, D J Kereiakes
1Department of Cardiology, Good Samaritan Hospital/Wright State University, Dayton, Ohio, USA. msathi@yahoo.com
Summary
Delayed severe thrombocytopenia after abciximab therapy is a rare complication. Early detection is crucial to prevent severe outcomes upon reexposure to this antiplatelet medication.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Abciximab is an antiplatelet medication used during percutaneous coronary interventions.
- Acute thrombocytopenia is a known, though not fully understood, side effect of abciximab therapy.
Observation:
- A case of delayed severe thrombocytopenia occurred after hospital discharge in a patient treated with abciximab for percutaneous coronary intervention.
- This delayed onset contrasts with the more typically immediate thrombocytopenic events.
Findings:
- The patient experienced severe thrombocytopenia several days post-procedure, necessitating medical intervention.
- The exact mechanism of abciximab-induced thrombocytopenia remains unclear, particularly for delayed presentations.
Implications:
- Recognizing delayed thrombocytopenia is critical for patient management.
- Subsequent exposure to abciximab in patients with a history of delayed thrombocytopenia may carry an increased risk of severe or profound platelet reduction.